The Association between Retinal Thickness Fluctuations and Visual Outcomes under Anti-Vascular Endothelial Growth Factor Therapy: A Systematic Review and Meta-Analysis
Authors:
- Bhadra PandyaBPBhadra Pandya
- Andrew MihalacheAMAndrew Mihalache
- Amin HatamnejadAHAmin Hatamnejad
- Justin GradJGJustin Grad
- Marko M. PopovicMPMarko M. Popovic
- David T.W. WongDWDavid T.W. Wong
Open Access
- 10 June 2024
- journal article
- research article
- Published by S. Karger AG in Ophthalmologica
- Vol. 247 (4) , 261-274
Abstract
Introduction: The objective of this study was to examine the association between retinal thickness (RT) fluctuations and best corrected visual acuity (BCVA) in eyes with neovascular AMD, macular edema secondary to RVO, and DME treated with anti-VEGF therapy. Methods: A systematic search of Ovid MEDLINE, EMBASE, and the Cochrane Library was performed from January 2006 to March 2024. Studies comparing visual or anatomic outcomes of patients treated with anti-VEGF therapy, stratified by magnitudes of RT fluctuation, were included. ROBINS-I and Cochrane RoB 2 tools were used to assess risk of bias, and certainty of evidence was evaluated with GRADE criteria. Meta-analysis was performed with a random-effects model. Primary outcomes were final BCVA and change in BCVA relative to baseline. Results: 15,725 articles were screened; 15 studies were identified in the systematic review and 5 studies were included in the meta-analysis. Final ETDRS VA was significantly worse in eyes with the highest level of RT fluctuation (weighted mean difference [WMD] = 7.86 letters; 95% CI, 4.97, 10.74; p < 0.00001; I2 = 81%; 3,136 eyes). RT at last observation was significantly greater in eyes with high RT fluctuations (WMD = −27.35 μm; 95% CI, −0.04, 54.75; p = 0.05; I2 = 88%; 962 eyes). Conclusions: Final visual outcome is associated with magnitude of RT fluctuation over the course of therapy. It is unclear whether minimizing RT fluctuations would help optimize visual outcomes in patients treated with anti-VEGF therapy. These findings are limited by a small set of studies, risk of bias, and considerable heterogeneity.Keywords
This publication has 32 references indexed in Scilit:
- Macular thickness fluctuation in neovascular age-related macular degeneration treated with anti-vascular endothelial growth factorCanadian Journal of Ophthalmology, 2022
- Association Between Visual Acuity and Residual Retinal Fluid Following Intravitreal Anti–Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular DegenerationJAMA Ophthalmology, 2022
- Fluctuations in Central Subfield Thickness Associated With Worse Visual Outcomes in Patients With Diabetic Macular Edema in Clinical Trial SettingAmerican Journal of Ophthalmology, 2021
- SCORE2 Report 17: Macular thickness fluctuations in anti-VEGF-treated patients with central or hemiretinal vein occlusionGraefe's Archive for Clinical and Experimental Ophthalmology, 2021
- Fluctuations in Macular Thickness in Patients with Retinal Vein Occlusion Treated with Anti–Vascular Endothelial Growth Factor AgentsOphthalmology Retina, 2020
- Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti–Vascular Endothelial Growth Factor AgentsJAMA Ophthalmology, 2020
- Tomographic Biomarkers Predicting Progression to Fibrosis in Treated Neovascular Age-Related Macular Degeneration: A Multimodal Imaging StudyOphthalmology Retina, 2018
- Relationship Between Visual Acuity and Retinal Thickness During Anti–Vascular Endothelial Growth Factor Therapy for Retinal DiseasesAmerican Journal of Ophthalmology, 2017
- Diurnal variation of macular oedema in CRVO: prospective studyGraefe's Archive for Clinical and Experimental Ophthalmology, 2008
- Temporal variation in diabetic macular edema measured by optical coherence tomographyOphthalmology, 2004